Evidence map›Paper›PMID 23295441›Full record

ArticleGastroenterology2013

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Daniela Sia, Yujin Hoshida, Augusto Villanueva, Sasan Roayaie, Joana Ferrer, Barbara Tabak, Judit Peix, Manel Sole, Victoria Tovar, Clara Alsinet and 13 more

Registry-linked trialAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04445532 (Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors), which is not on this map. Cited by 306 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
306citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04445532 unknown statusnot on this mapstarted 2020, after this paper: background citation

Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors

TypeobservationalSponsorPeking Union Medical College HospitalRan2020 to 2025Enrolled450ConditionsHepatocellular Carcinoma, Cholangiocarcinoma, Gallbladder Cancer, Biliary Tract CancerArmsGene expression analysis, Genomic analysis, Protein expression analysis, Proteomic profiling, Polymerase chain reaction
3 · Its place in the literature

Who cites it

306 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Co-repression ofbioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Review
  17. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  18. Review
  19. Article
  20. Review

246 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Daniela SiaBarcelona-Clínic Liver Cancer Group (HCC Translational Research Laboratory, Liver Unit, Pathology Department), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Liver Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
Yujin Hoshida
Augusto Villanueva
Sasan Roayaie
Joana Ferrer
Barbara Tabak
Judit Peix
Manel Sole
Victoria Tovar
Clara Alsinet
Helena Cornella
Brandy Klotzle
Jian-Bing Fan
Christian Cotsoglou
Swan N Thung
Josep Fuster
Samuel Waxman
Juan Carlos Garcia-Valdecasas
Jordi Bruix
Myron E Schwartz
Rameen Beroukhim
Vincenzo Mazzaferro
Josep M Llovet

Funding

The Cell-Of-Origin of Human CancersU54CA143798 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MICHOR, FRANZISKA · 2009 to 2014
$11.2M
Molecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6M
Integrative genomic analysis in hepatocellular carcinomaR01DK076986 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LLOVET, JOSEP M · 2007 to 2011
$1.3M
High-resolution genome-wide mapping of structural mutations in prostate cancerK08CA122833 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN · 2007 to 2011
$697k
NCI NIH HHS K08 CA122833NCI NIH HHS K08CA122833NCI NIH HHS U54 CA143798NCI NIH HHS U54CA143798NIDDK NIH HHS 1R01DK076986-01NIDDK NIH HHS R01 DK076986NIDDK NIH HHS R01 DK099558
6 · The paper itself

Abstract

BACKGROUND &

aimsCholangiocarcinoma, the second most common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma. We performed an integrative genomic analysis of ICC samples from a large series of patients.

methodsWe performed a gene expression profile, high-density single-nucleotide polymorphism array, and mutation analyses using formalin-fixed ICC samples from 149 patients. Associations with clinicopathologic traits and patient outcomes were examined for 119 cases. Class discovery was based on a non-negative matrix factorization algorithm and significant copy number variations were identified by Genomic Identification of Significant Targets in Cancer (GISTIC) analysis. Gene set enrichment analysis was used to identify signaling pathways activated in specific molecular classes of tumors, and to analyze their genomic overlap with hepatocellular carcinoma (HCC).

resultsWe identified 2 main biological classes of ICC. The inflammation class (38% of ICCs) is characterized by activation of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation. The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC. Copy number variation-based clustering was able to refine these molecular groups further. We identified high-level amplifications in 5 regions, including 1p13 (9%) and 11q13.2 (4%), and several focal deletions, such as 9p21.3 (18%) and 14q22.1 (12% in coding regions for the SAV1 tumor suppressor). In a complementary approach, we identified a gene expression signature that was associated with reduced survival times of patients with ICC; this signature was enriched in the proliferation class (P < .001).

conclusionsWe used an integrative genomic analysis to identify 2 classes of ICC. The proliferation class has specific copy number alterations, activation of oncogenic pathways, and is associated with worse outcome. Different classes of ICC, based on molecular features, therefore might require different treatment approaches.

Indexed as

Gene Expression Regulation, NeoplasticAgedBile Duct NeoplasmsBile Ducts, IntrahepaticBiopsy, NeedleCholangiocarcinomaDatabases, FactualDisease ProgressionDNA Copy Number VariationsDNA Mutational AnalysisFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization

Identifiers

PMID23295441
PMCPMC3624083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.